# First Affiliated Hospital of Guangzhou Medical University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/first-affiliated-hospital-of-guangzhou-medical-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 37.9 |
| Citations | 2,376,377 |
| City | Guangzhou |
| Country | CN |
| Description | First Affiliated Hospital of Guangzhou Medical University is a research organisation in Guangzhou, CN. OpenAlex records 14,845 works and 2,376,377 citations for it. 6,678 researchers list it as their most recent affiliation. |
| Homepage | http://www.gyfyy.com/cn/index.aspx |
| OpenAlex ID | https://openalex.org/I4210098361 |
| Researchers | 6,678 |
| ROR ID | https://ror.org/00z0j0d77 |
| Type | healthcare |
| Works | 14,845 |

## University papers

Showing 12 of 42.

- [Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China](https://scholariq.org/papers/cancer-patients-in-sars-cov-2-infection-a-nationwide-analysis-in-china/)
- [Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis](https://scholariq.org/papers/comorbidity-and-its-impact-on-1590-patients-with-covid-19-in-china-a-nationwide/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19](https://scholariq.org/papers/development-and-validation-of-a-clinical-risk-score-to-predict-the-occurrence-of/)
- [Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography](https://scholariq.org/papers/clinically-applicable-ai-system-for-accurate-diagnosis-quantitative-measurements/)
- [Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis](https://scholariq.org/papers/comorbidity-and-its-impact-on-1-590-patients-with-covid-19-in-china-a-nationwide/)
- [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-anlotinib-as-a-third-line-or-further-treatment-on-overall-survival-of/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-of-the-mage-a3-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients/)
- [EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy](https://scholariq.org/papers/ebv-driven-lmp1-and-ifn-up-regulate-pd-l1-in-nasopharyngeal-carcinoma/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry](https://scholariq.org/papers/impact-of-examined-lymph-node-count-on-precise-staging-and-long-term-survival-of/)

## University researchers

- [Wei Huang](https://scholariq.org/researchers/wei-huang-3/)
- [Weitao Zhuang](https://scholariq.org/researchers/weitao-zhuang/)

## University top topics

Showing 8 of 25.

- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.